Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2017-A00256-47 | Other Identifier | ID-RCB number, ANSM |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
ECMO has improved the outcome of heart or respiratory failure and carcinogenic shock and are increasingly used. However bleeding complications occurring in up to 50% of patients are poorly understood and worsen the overall results. The aim is to investigate the occurence of bleeding and its frequency according to the type of ECMO either veno-arterial or veno-venous. The investigators also want to assess the relation of bleeding with von Willebrand Factor defects.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Frequency of major bleeding | Number of major bleeding events (BARC classification ) occurring within the time course of support by ECMO | During ECMO support, up to 3 weeks after implantation |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With Abnormal VWF functional activities and multimeric profile according to the type of ECMO support (VA- or VV-ECMO) | Willebrand Factor abnormalities according to the type of ECMO support (VA- or VV-ECMO) | 1 hour, 24 hours and day seven after implantation |
| Number of Participants With Abnormal VWF functional activities and multimeric profile before and after the first reduction in VA-ECMO flow rate |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
patients older than 18 years receiving either veno-arterial or even-venous ECMO and referred at Lille University Hospital
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Antoine RAUCH, MD,PhD | University Hospital, Lille | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CH ARRAS | Arras | France | ||||
| CH Boulogne |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 40020783 | Background | Moussa MD, Abou-Arab O, Staessens S, Jungling M, Labreuche J, Lamer A, Beyls C, Rousse N, Rauch A, Loobuyck V, Beaudeux C, Pierache A, Deblauwe D, Corseaux D, Dubernet M, Guilbart M, Thellier L, Mahjoub Y, Juthier F, Dupont H, De Meyer SF, Vincentelli A, Susen S, Robin E. Comparison of the effects of phosphorylcholin versus heparin-based surface coating on clinical and histologic outcomes during veno-arterial extracorporeal membrane oxygenation support: a propensity score weighted analysis. J Thromb Haemost. 2025 Jun;23(6):1879-1892. doi: 10.1016/j.jtha.2025.02.020. Epub 2025 Feb 26. | |
| 37883587 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D014842 | von Willebrand Diseases |
| D006470 | Hemorrhage |
| ID | Term |
|---|---|
| D025861 | Blood Coagulation Disorders, Inherited |
| D001778 | Blood Coagulation Disorders |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Willebrand Factor abnormalities according to residual arterial pulsatility levels under VA-ECMO |
| During ECMO support, up to 3 weeks after implantation |
| Number of Participants With Abnormal VWF functional activities and multimeric profile in 2 groups defined by the level of pulse pressure measured before ECMO weaning: high (> median) or low (< median) pulse pressure | Willebrand Factor abnormalities according to residual arterial pulsatility levels under VA-ECMO | During ECMO support, up to 3 weeks after implantation |
| Number of Participants With major bleeding events (BARC classification) before and after the first reduction in VA-ECMO flow rate | Willebrand Factor abnormalities according major bleeding events under VA-ECMO | During ECMO support, up to 3 weeks after implantation |
| Number of Participants With major bleeding events (BARC classification) in 2 groups defined by the level of pulse pressure measured before ECMO weaning: high (> median) or low (< median) pulse pressure | Willebrand Factor abnormalities according major bleeding events under VA-ECMO | During ECMO support, up to 3 weeks after implantation |
| Frequency of major bleeding events according to diabetes status | Number of major bleeding events (BARC classification ) occurring within the time course of support by ECMO in patients with and without diabetes | During ECMO support, up to 3 weeks after implantation |
| Frequency of major thrombotic events according to diabetes status | Number of major thrombotic events (stroke, transient ischemic attack, acute limb ischemia, ECMO thrombosis) occurring within the time course of support by ECMO in patients with and without diabetes | During ECMO support, up to 3 weeks after implantation |
| Frequency of pro-thrombotic biological abnormalities | Measurement of plasma free hemoglobin, leuco-platelet aggregates and neutrophil extracellular traps levels | During ECMO support, up to 3 weeks after implantation |
| Boulogne-sur-Mer |
| France |
| CH DOUAI | Douai | France |
| CH Dunkerque | Dunkirk | 59385 | France |
| Hôpital Cardiologie, CHU | Lille | France |
| Ch Tourcoing | Tourcoing | France |
| Ch Valenciennes | Valenciennes | France |
| Result |
| Rauch A, Dupont A, Rosa M, Desvages M, Le Tanno C, Abdoul J, Didelot M, Ung A, Ruez R, Jeanpierre E, Daniel M, Corseaux D, Spillemaeker H, Labreuche J, Pradines B, Rousse N, Lenting PJ, Moussa MD, Vincentelli A, Bordet JC, Staels B, Vincent F, Denis CV, Van Belle E, Casari C, Susen S. Shear Forces Induced Platelet Clearance Is a New Mechanism of Thrombocytopenia. Circ Res. 2023 Oct 27;133(10):826-841. doi: 10.1161/CIRCRESAHA.123.322752. Epub 2023 Oct 26. |
| D020147 | Coagulation Protein Disorders |
| D001791 | Blood Platelet Disorders |
| D006474 | Hemorrhagic Disorders |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |